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Dietary guidance normalizes large intestinal endocrine cell
densities in patients with irritable bowel syndrome
T Mazzawi1,2,3, T Hausken2,3, D Gundersen4 and M El-Salhy1,2,3
BACKGROUND/OBJECTIVES: To determine the large intestinal endocrine cell types affected following dietary guidance in patients
with irritable bowel syndrome (IBS).
SUBJECTS/METHODS: The study included 13 IBS patients and 13 control subjects. The patients received three sessions of
individualized dietary guidance. Both the control subjects and the patients were scheduled for colonoscopies at baseline and again
for the patients at 3–9 months after dietary guidance. Biopsy samples were taken from the colon and rectum and were
immunostained for all types of large intestinal endocrine cells. The endocrine cells were quantified using computerized image
analysis.
RESULTS: The daily total consumption (mean± s.e.m. values) of fruits and vegetables rich in FODMAPs (fermentable
oligosaccharides, disaccharides, monosaccharides and polyols) decreased significantly from 16.2 ± 5.3 g before receiving dietary
guidance to 9.2 ± 3.2 g after receiving dietary guidance (P= 0.02). In the total colon, the densities of serotonin cells were 46.8 ± 8.9,
10.5 ± 2.1 and 22.6 ± 3.2 cells/mm2 in control subjects and in IBS patients before and after receiving dietary guidance, respectively
(P= 0.007); the corresponding densities of peptide YY cells were 11.6 ± 1.8, 10.8 ± 1.7 and 16.8 ± 2.1 cells/mm2, respectively
(P= 0.06). The cell densities for both serotonin and peptide YY did not change significantly in the rectum. The densities of
somatostatin cells in the rectum were 13.5 ± 3.0, 13.2 ± 3.0, and 22.3 ± 3.2 cells/mm2 for control subjects and for IBS patients before
and after receiving dietary guidance, respectively (P= 0.01).
CONCLUSIONS: The densities of the large intestinal endocrine cells tend to normalize following dietary guidance that may have
contributed to the improvement of the patients with IBS symptoms.
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INTRODUCTION
Irritable bowel syndrome (IBS) is a common chronic functional
gastrointestinal (GI) disorder.1 Besides its associated morbidity,
IBS patients exhibit a high consumption of health-care resources
that represents an economic burden to society as a whole.1–4
There is increasing evidence that IBS can result from dysfunction
of the GI neuroendocrine system and GI endocrine cells in
particular.5–16
The GI endocrine cells are scattered among the epithelial cells
lining the GI lumen.17–19 These endocrine cells interact with the GI
luminal contents (especially nutrients) and respond by releasing
specific hormones that affect different functions of the GI
tract.5,20–31
Approximately two-thirds of IBS patients relate their symptom
development to diet.32,33 Dietary guidance has been proven to
reduce the symptoms and improve the quality of life of IBS
patients.34,35
A previous study found that changing the dietary intake by the
provision of individualized dietary guidance altered the large
intestinal total endocrine cells as detected by a general marker for
endocrine cells (chromogranin A).36 The observed change in
chromogranin A cell density after receiving dietary guidance was
toward the normal values of controls. However, which endocrine
cell type was affected is not clear.36
The present study was undertaken to determine the types of
large intestinal endocrine cells that are affected after receiving
dietary guidance. The study was performed on the same cohort of
IBS patients in whom the total population of endocrine cells was
observed after receiving dietary guidance.36
MATERIALS AND METHODS
Patients and controls
Patients of both sexes aged between 18 and 70 years and referred to the
Division of Gastroenterology, Stord Hospital, Norway, who fulfilled Rome-III
criteria for IBS diagnosis were included in the study. The exclusion criteria
were being pregnant or lactating women patients with serious psychiatric
or any organic/systemic diseases, drug abuse or previous abdominal
surgery, with the exception of appendectomy, caesarean section or
hysterectomy. Seven patients did not use any kind of medication. The
remaining patients, however, used one or a combination of the following:
proton pump inhibitors (n= 4), thyroxin substitution tablets (n= 2), asthma
inhalators (n= 1), angiotensin II receptor antagonist antihypertensive
tablets (n=1), antiallergic tablets (n= 3), contraceptive pills (n=2) and
antidepressants/anxiolytics (n= 2). These patients were instructed not to
take any kind of proton pump inhibitors 1 week before starting or during
the study.
A control group of 13 subjects was included in the study. They
comprised 9 females and 4 males with a mean age of 54 years (range
26–70 years). Four of the control subjects underwent colonoscopies
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because of GI bleeding that identified the source as hemorrhoids (n= 3) or
angiodysplasia (n= 1), whereas the other 9 control subjects underwent
colonoscopies because of health worries caused by a family member being
diagnosed with GI cancer.
The study was performed in accordance with the Declaration of Helsinki
and was approved by the local Committee for Medical Research Ethics
West, Bergen, Norway. All patients provided both oral and written consents
to participate.
Study design
Forty-six patients (35 females and 11 males) with mean age of 35 years
(range 18–69 years) were included in the study. All patients underwent
physical examinations, and blood tests were performed to exclude
inflammation, infection and other organic diseases. The patients were
scheduled for three 45-min sessions of individualized dietary guidance,
with a nurse experienced in diet and IBS, at intervals of at least 2 weeks.
The patients were examined with colonoscopies before the first session
and at 3–9 months (median, 4 months) following the third session of
dietary guidance.
Individualized dietary guidance
Dietary guidance was delivered orally with the help of charts, and in
written illustrations. During the first session, the patients received general
information about IBS, with emphasis on the importance of a regular and
healthy eating pattern and on the food items that worsen IBS symptoms
such as insoluble dietary fiber and poorly absorbable FODMAPs
(fermentable oligosaccharides, disaccharides, monosaccharides and poly-
ols). The patients were informed that lactose-free milk and other lactose-
free dairy products do not provoke IBS symptoms and hence they were
allowed to consume such products daily during the study. The patients
were supposed to test diets that were either rich or poor in protein, fat or
carbohydrate, and to register for 2 weeks in a diary their daily consumption
of food and fluids along with any associated symptoms, including the
frequency and degree of abdominal pain and abdominal distension
and the stool frequency and consistency. The consumption of food
supplements containing probiotics, antibiotics and other medications was
prohibited during the study unless otherwise specified.
In the second session, the nurse focused mainly on briefly repeating the
information given during the first session and on using the patient’s diary
to identify the food items that triggered IBS symptoms. Based on the
obtained information, the patients were asked to alter their diet
proportions of protein, fat and carbohydrate, avoid FODMAPs-rich items
as well as insoluble fiber and to consume vegetables and fruits that
contained lower amounts of FODMAPs and insoluble fiber.
During the third session, each patient gave feedback about the dietary
guidance to the nurse, and together with the nurse designed a suitable
diet for the patient to follow until the end of the study.
Dietary assessment
Dietary intake was assessed using the MoBa food frequency questionnaire.
This questionnaire reports the frequency and the portion sizes of food
stuffs and beverages consumed over a defined period of time. Data
analysis was conducted using software to calculate the nutrient content of
the diet. The MoBa food frequency questionnaire was developed and
validated by the Norwegian Institute of Public Health in Oslo, Norway.37,38
This questionnaire inquires about the consumption of 225 foodstuffs and
identifies the dietary habits of the participant, including the intake of any
oral supplements, according to typical Norwegian meal patterns. The
participants completed the MoBa food frequency questionnaire form
before the first session and again at least 3 months after the third session
of individualized dietary guidance.34
Colonoscopies, biopsy sampling, histopathology and
immunohistochemistry
Both the patients and controls were scheduled to receive colonoscopies,
during which four biopsy samples were taken from each segment of the
large intestine. The biopsy samples were then divided according to the
segment they were taken from into right colon, left colon and rectum,
where the right colon referred to the cecum, the ascending colon and the
right half of the transverse colon. The left colon referred to the left half
of the transverse colon, the descending colon and the sigmoid colon.
In the rectum, biopsy samples were taken from the dorsal wall ∼ 15 cm
from the anus.
The biopsy samples were fixed in 4% buffered paraformaldehyde
overnight, embedded in paraffin and cut into sections with a thickness of
5 μm. The biopsy samples were examined histopathologically. They
were stained with hematoxylin–eosin and immunostained using the
Avidin-Biotin complex (ABC) method with the Vectastain ABC kit (Vector
Laboratories, Burlingame, CA, USA) and the chromogen 3,3′-diaminoben-
zidine peroxidase substrate (DAB) kit (Vector Laboratories). The immunos-
taining method has been described in detail previously.13 In brief, the
sections were incubated for 2 h with the primary antibodies and then for
another 30min with biotinylated swine anti-mouse IgG (in the case of
monoclonal antibodies) or goat anti-rabbit IgG (in the case of polyclonal
antibodies), both diluted to 1:200, and for 30min with ABC diluted to
1:200. The slides were submerged in DAB and counterstained with
hematoxylin. Incubation was carried out at room temperature. The primary
antibodies used were monoclonal mouse anti-serotonin (code no. 5HT-209,
Dako, Glostrup, Denmark), polyclonal anti-porcine peptide YY (PYY; code
PYY 11A, Alpha Diagnostic, San Antonio, TX, USA), polyclonal rabbit
antisynthetic human pancreatic polypeptide (code no. 114, Diagnostic
Biosystems, Pleasanton, CA, USA), polyclonal rabbit anti-porcine
oxyntomodulin (code BP508, Acris Antibodies, Herford, Germany) and
polyclonal rabbit antisynthetic human somatostatin (code no. A566, Dako);
these antibodies were used in dilutions of 1:1500, 1:1000, 1:800, 1:400 and
1:200, respectively.
Computerized image analysis
The densities of various types of endocrine cell were quantified using
computer software Cell^D (Olympus, Tokyo, Japan). The number of
immunoreactive endocrine cells and the area of the epithelial cells were
measured in 10 randomly chosen fields using a × 40 objective. Each field
represented a tissue area of 0.14mm2. The density of endocrine cells is
expressed herein as the number of cells per square mm of epithelium.
Table 1. Demographic characteristics of participants
IBS subtype/controls Number Age (mean)a Females/males
IBS-D 6 30–44 (37.2) 2/4
IBS-C 5 27–42 (32.4) 4/1
IBS-M 2 21–23 (22) 2/0
Controls 13 26–70 (54) 9/4
Abbreviations: IBS, irritable bowel syndrome; IBS-C, IBS patients with
constipation as a predominant symptom; IBS-D, IBS patients with diarrhea
as the predominant symptom; IBS-M, IBS patients with mixed diarrhea and
constipation. aYears.
Table 2. Densities of serotonin- and PYY-immunoreactive cells in the
total colon, right colon and left colon of control subjects and of IBS
patients before and after receiving dietary guidance







Total colon 46.8± 8.9 10.5± 2.1 22.6± 3.2 0.007b
Right colon 25.9± 5.4 1.2± 0.8 10.7± 1.6 o0.0001c
Left colon 20.9± 4.8 8.9± 1.7 10.6± 1.9 0.53
PYY
Total colon 11.6± 1.8 10.8± 1.7 16.8± 2.1 0.06
Right colon 3.9± 0.8 2.9± 0.8 5.5± 1.1 0.1
Left colon 7.7± 1.4 7.9± 1.0 11.5± 1.1 0.04a
Abbreviations: IBS, irritable bowel syndrome; PYY, peptide YY. Data are
presented as mean± s.e.m. aPo0.05, bPo0.01 and cPo0.0001.
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All quantifications were performed by one person (TM) who was not aware
of the identity of the slides.
Statistical analysis
The Kruskal–Wallis nonparametric test with Dunn’s test as a post test was
used to compare between the controls and patients before dietary
guidance and also between controls and patients after dietary guidance.
The paired t-test was used to compare patients before and after receiving
dietary guidance. The data are presented as mean± s.e.m. values. P-values
of o0.05 were considered significant.
RESULTS
Patients and controls
Forty-six patients were included in the study and received sessions
of individualized dietary guidance. After the first session and
colonoscopy, four patients were excluded after being diagnosed
with celiac disease (n= 2) and lupus (n= 1) and because of
technically difficult colonoscopy (n= 1). The remaining patients
(n= 42) went through the second session of individualized dietary
guidance. Two patients were also excluded during the study
because of pregnancy (n= 1) and moving abroad (n= 1). Forty
patients received the third session of individualized dietary
guidance. Following the third session, 24 patients withdrew their
consent, either because of symptom improvement after receiving
Figure 1. Serotonin cell densities in the total colon (A), right colon
(B) and left colon (C) of IBS patients before and after receiving
dietary guidance. The dashed lines labeled ‘a’ and ‘c’ indicate the
upper and lower limits of the 95% confidence interval for control
subjects, respectively, whereas line ‘b’ indicates the mean serotonin
cell density. **Po0.01, ****Po0.0001.
Figure 2. Serotonin-immunoreactive cells in the total colon of a
control subject (a) and of an IBS patient before (b) and after (c)
receiving dietary guidance.
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dietary guidance and/or because they were unwilling for a second
colonoscopy to be performed. Additional two patients were
excluded because of noncompliance (n= 2). One patient was
excluded because of a bout of gastroenteritis under the study
(n= 1). Thus, 13 of the original 46 patients completed the entire
study, comprising 8 females and 5 males with a mean age of 34
years (range 20–45 years). The demographic characteristics are
summarized in Table 1.
Dietary assessment
The change in diet in the present study has been described in
detail elsewhere.34 In brief, the daily total consumption of fruits
and vegetables rich in FODMAPs decreased significantly from
16.2 ± 5.3 g before receiving dietary guidance to 9.2 ± 3.2 g after
receiving dietary guidance (P= 0.02). However, the daily con-
sumption of fiber did not differ significantly between before
receiving dietary guidance (27.4 ± 2.5 g) and after receiving dietary
guidance (23.1 ± 2.2 g, P= 0.09).34
Colonoscopies, histopathology and immunohistochemistry
The colonoscopies indicated that the colon and rectum were
normal both macroscopically and microscopically in patients as
well as controls, with no signs of microscopic colitis. Immuno-
reactive endocrine cells were found in the mucosa of both the
colon and rectum of the patients and controls. These cells were
either basket or flask shaped, and sometimes exhibited a long
basal cytoplasmic process. The numbers of pancreatic polypep-
tide- and oxyntomodulin (enteroglucagon)-immunoreactive cells
in the biopsy samples of the colon and rectum used in the study
were too low to allow reliable quantification. There were also too
few somatostatin cells in the colon to allow reliable quantification.
Computerized image analyses
Colon
Serotonin cell density: The densities of serotonin cells in the
controls and patients are listed in Table 2 and illustrated in
Figures 1 and 2. The density of serotonin cells in the total colon
and the right colon of IBS patients increased significantly
(P= 0.007 and Po0.0001, respectively) after receiving dietary
guidance. The density of serotonin cells in the left colon also
increased after receiving dietary guidance, but this increase was
not statistically significant (P= 0.53). The densities of serotonin
cells in controls and IBS subtypes before and after receiving
guidance are listed in Table 3.
PYY cell density: The densities of PYY cells in the controls and
patients are summarized in Table 2 and illustrated in Figure 3. The
density of PYY cells in the left colon of IBS patients increased
significantly (P= 0.04) after receiving dietary guidance. The
densities of PYY cells also increased in the total colon and the
right colon following dietary guidance, but the change did not
reach the cutoff for statistical significance (P= 0.06 and P= 0.1,
respectively). The densities of PYY cells in controls and IBS
subtypes before and after receiving guidance are listed in Table 3.
Rectum. The densities of serotonin, PYY and somatostatin cells in
controls and patients are reported in Table 4.
Serotonin cell density: The serotonin cell density in the rectum
of IBS patients did not differ significantly (P= 0.06) between before
and after receiving dietary guidance (Figure 4A).
PYY cell density: The density of PYY cells in the rectum of IBS
patients did not change significantly (P= 0.13) after receiving
dietary guidance (Figure 4B).
Somatostatin cell density: The somatostatin cell density of IBS
patients increased significantly (P= 0.01) after receiving dietary
guidance (Figure 4C).
Table 3. Densities of serotonin- and PYY-immunoreactive cells in the total colon, right colon and left colon of controls and patients with different IBS
subtypes before and after receiving dietary guidance


















Total colon 46.8± 8.9 IBS-D 11.17± 3.4 19.83± 3.7 0.009b 0.2 0.12
IBS-C 11.75± 3.8 22.75± 8.1 0.06 0.26 0.24
IBS-M 6.0± 2.0 30.5± 0.5 0.16 0.66 0.06
Right colon 25.9± 5.4 IBS-D 2.16± 1.6 10.3± 1.7 0.002b 0.22 0.009b
IBS-C 0.75± 0.48 11.5± 4.7 0.03a 0.43 0.1
IBS-M 0 10.7± 2.6 0.02a 0.42 0.05
Left colon 20.9± 4.8 IBS-D 9.0± 2.9 9.5± 2.1 0.39 0.59 0.89
IBS-C 10.0± 3.1 9.0± 3.7 0.42 0.33 0.83
IBS-M 6.0± 2.0 18.0± 3.0 0.39 0.9 0.25
PYY
Total colon 11.6± 1.8 IBS-D 11.17± 2.4 19.17± 2.5 0.9 0.051 0.04a
IBS-C 12.5± 3.5 11.5± 3.3 0.9 0.9 0.83
IBS-M 6.5± 3.5 20.5± 7.5 0.43 0.37 0.42
Right colon 3.9± 0.8 IBS-D 3.83± 1.3 6.0± 1.4 0.9 0.31 0.39
IBS-C 3.5± 1.7 4.3± 2.5 0.9 0.9 0.78
IBS-M 0.33± 0.33 6.3± 2.4 0.09 0.8 0.15
Left colon 7.7± 1.4 IBS-D 7.3± 1.7 13.2± 1.4 0.9 0.04a 0.002b
IBS-C 9.4± 1.5 8.6± 1.6 0.95 0.9 0.72
IBS-M 6.0± 3.0 13.5± 3.5 0.87 0.25 0.45
Abbreviations: IBS, irritable bowel syndrome; IBS-C, IBS patients with constipation as a predominant symptom; IBS-D, IBS patients with diarrhea as the
predominant symptom; IBS-M, IBS patients with mixed diarrhea and constipation; PYY, peptide YY. Data are presented as mean± s.e.m. aPo0.05 and bPo0.01.
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DISCUSSION
The dropout rate in the present study was 52%, somewhat higher
than previously reported rates (33–48%).35,39–42 This higher
dropout rate could be explained by the demanding design of
the study, involving two colonoscopies and requiring the patients
to follow a strict diet for at least 3 months. Moreover, an additional
20% of the patients were excluded from the study for other
reasons (diagnosis of celiac disease, pregnancy, moving abroad,
noncompliance, gastroenteritis and technical difficulties experi-
enced during the colonoscopy). However, despite the small
number of the sample who completed the study, changing the
diet in these patients was shown to have a significant impact on
the large intestinal endocrine cells. It is worth mentioning that
neither age nor gender affects the densities of the endocrine cells
in the large intestine.36,43
A previous study involving the same cohort of IBS
patients investigated in the present study36 found that the
total endocrine cells, as detected by chromogranin A, changed
in the colon, but not in the rectum. The present findings
show that these changes in the colon are brought about
by changes in serotonin and PYY cells. The elevation in the
density of somatostatin cells in the rectum seen in the
Figure 3. PYY cell densities in the total colon (A), right colon (B) and
left colon (C) of IBS patients before and after receiving dietary
guidance. The symbols are the same as in Figure 1. *Po0.05.
Table 4. Densities of serotonin-, PYY- and somatostatin-
immunoreactive cells in the rectum of control subjects and of IBS
patients before and after receiving dietary guidance







Serotonin 37.7± 10.5 31.9± 6.4 19.6± 4.5 0.06
PYY 32.5± 5.1 38.4± 5.0 31.5± 3.7 0.13
Somatostatin 13.5± 3.0 13.2± 3.0 22.3± 3.2 0.01a
Abbreviations: IBS, irritable bowel syndrome; PYY, peptide YY. Data are
presented as the mean± s.e.m. aPo0.05.
Figure 4. Cell densities of (A) serotonin, (B) PYY and (C) somatostatin
in the rectum of IBS patients before and after receiving dietary
guidance. The symbols are the same as in Figure 1. *Po0.05.
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present study does not seem to have affected the total densities
of endocrine cells.
Serotonin is known to activate the submucosal sensory branch
(Meissner’s plexus) of the enteric nervous system that conveys
sensation from the GI tract to the central nervous system and
modulates the visceral sensitivity of the GI tract.7,44–47 Serotonin
also stimulates the motility of the large intestine, and accelerates
the transit time through both the small and large intestines.44–52
The serotonin cell density has been found to be low in patients
with IBS.11 After receiving dietary guidance in the present study,
the serotonin cell density in the colon increased significantly
toward the values for the control subjects. The serotonin cell
density in the rectum of IBS patients has been reported to be
normal.9 The serotonin cell density in the rectum remained
unchanged in IBS patients in the present study after receiving
dietary guidance.
PYY stimulates the absorption of water and electrolytes, and is
considered to be a major regulator of the ‘ileal brake’.7,53 The cell
density of PYY has been reported to be low in the colon11 and
rectum9 of IBS patients. The cell density of PYY increased
significantly only in the left colon toward the values of control
subjects, after receiving dietary guidance. The increase in the PYY
cell densities in the total and right colon was not significant, and
this could be a type II error because of the small sample size being
studied. The cell densities of PYY did not significantly change in
the rectum.
A previous study on the same cohort of IBS patients showed a
significant improvement in pain (Po0.001) and diarrhea
(Po0.05) domains but not in constipation using Birmingham
IBS symptom questionnaire after receiving dietary guidance
compared with before guidance.34 It is possible that the significant
changes in the cell densities of serotonin and PYY in IBS-D patients
could be related to the observed symptomatic changes after
receiving dietary guidance in the mentioned article. The different
changes in the cell densities in different parts of the colon could
be a type II error because of the small sample size. In the same
manner, the nonsignificant changes in the cell densities in IBS-C
patients might be related to the nonsignificant change in the
constipation domain of Birmingham IBS symptom questionnaire
after receiving dietary guidance.34
Somatostatin inhibits intestinal motility and exocrine and
neuroendocrine secretion.8,54 The rectal somatostatin cell density
has been found to be higher in patients with IBS.9 The
somatostatin cell density in the rectum increased significantly
after receiving dietary guidance. This increase in somatostatin cell
density is difficult to explain. It is possible that it may be caused by
a compensatory reaction to the increased cell density of PYY after
receiving dietary guidance.
The changes in the endocrine cell densities after receiving
dietary guidance differed between the colon and rectum,
probably because of their different functions: the colon absorbs
water, sodium and some fat-soluble vitamins, whereas the rectum
acts only as a fecal reservoir before defecation.13
Nutrients in the lumen of the GI tract are the main triggers for
the endocrine cells releasing various GI hormones that control and
regulate several functions of the GI tract.8,55 The stem cells in the
GI tract require between 2 and 6 days to differentiate into
different endocrine cells.56,57 It can therefore be speculated that
changing the pattern of food intake can alter the differentiation of
the endocrine cells.
In conclusion, this study is the first to show that the densities of
the endocrine cells in the large intestines are affected by the type
of food consumed. A change in diet of IBS patients following the
provision of dietary guidance can normalize the densities of these
endocrine cells and recover their malfunctioning, and may have
resulted in the improvement of IBS symptoms.
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